Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jun 13;40(6):592-594.
doi: 10.1016/j.ccell.2022.05.012.

Response-based molecular subtyping-emergence of the third generation of breast cancer subtypes

Carsten Denkert  1 , Sibylle Loibl  2
Affiliations
Free article
Comment

Response-based molecular subtyping-emergence of the third generation of breast cancer subtypes

Carsten Denkert et al. Cancer Cell. .
Free article

Abstract

The therapeutic landscape of breast cancer is becoming increasingly complex. In this issue of Cancer Cell, Wolf et al. present a breast cancer classification scheme that allows for better prediction of treatment response and can be continuously adapted to guide prioritization of new treatments.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests C.D. reports grants from European Commission H2020, grants from German Cancer Aid Translational Oncology, and grants from German Breast Group; personal fees from Novartis, personal fees from Roche, personal fees from MSD Oncology, personal fees from Daiichi Sankyo, personal fees from AstraZeneca, personal fees from Molecular Health, grants from Myriad, and personal fees from Merck, outside the submitted work; C.D. is cofounder of Sividon Diagnostics. In addition, C.D. has a patent VMScope digital pathology software with royalties paid, a patent WO2020109570A1—cancer immunotherapy pending, and a patent WO2015114146A1 and WO2010076322A1-therapy response issued. S.L. reports grants and other from Abbvie; other from Amgen; grants and other from AstraZeneca; other from BMS; grants and other from Celgene; other from Eirgenix; other from GSK; grants, non-financial support, and other from Gilead; other from Lilly; other from Merck; grants, non-financial support, and other from Novartis; grants, non-financial support, and other from Pfizer; other from Pierre Fabre; non-financial support and other from Seagen; grants, non-financial support, and other from Daiichi-Sankyo; other from Sanofi; grants, non-financial support, and other from Roche, outside the submitted work. In addition, S.L. has a patent EP14153692.0 pending, a patent EP21152186.9 pending, a patent EP15702464.7 issued, a patent EP19808852.8 pending, and a patent Digital Ki67 Evaluator with royalties paid.

Comment on

Publication types

LinkOut - more resources